Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Prospectus
Announcements
2021.09.01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...
2021.08.26
ANNOUNCEMENT (1) PROPOSED CHANGE OF BUSINESS SCOPE; AND (2) PROPOSED AMENDMENT O...
2021.08.26
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
2021.08.16
DATE OF BOARD MEETING
2021.08.04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...
2021.07.05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...
2021.06.23
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF ...
2021.06.10
VOLUNTARY ANNOUNCEMENT “INHIXA” OBTAINS APPROVAL FROM BOSNIA AND HERZEGOVINA
2021.06.10
VOLUNTARY ANNOUNCEMENT - "INHIXA" OBTAINS APPROVAL FROM BOSNIA AND HERZEGOVINA
2021.06.07
THE GROUP’S ENOXAPARIN SODIUM INJECTION OBTAINS MARKETING APPROVAL FROM NATIONAL...
第一页
上一页
10
11
12
13
14
下一页
最后一页
